Mancini Anthony 4

What Happened
Anthony Mancini, Chief Global Commercialization Officer at Revolution Medicines (RVMD), exercised 3,120 stock options on April 27, 2026 by paying $33.62 per share (total cost $104,894). The same day he sold those 3,120 shares in multiple open‑market trades for aggregate proceeds of approximately $413,129 (three blocks at weighted average prices of $131.66, $132.88 and $134.34). The transactions were executed under a prearranged 10b5‑1 trading plan.

Key Details

• Transaction date: 2026-04-27 (filed 2026-04-29). Filing appears timely.
• Exercise: 3,120 shares acquired at $33.62 each, total $104,894 (Form 4 code M).
• Sales: 1,671 shares @ $131.66 (≈ $220,007); 1,049 shares @ $132.88 (≈ $139,388); 400 shares @ $134.34 (≈ $53,734). Total sales ≈ $413,129. Sales executed in multiple trades; reported prices are weighted averages (see footnotes for trade price ranges).
• Derivative reporting: a corresponding derivative disposition of 3,120 units was reported at $0.00 (standard reporting for option exercise/cancellation).
• Holdings note: Filing includes 54,400 Restricted Stock Units (RSUs) referenced in footnote; total shares beneficially owned after the transactions are not specified in the excerpt.
• Plan/footnotes: Transactions were made pursuant to a 10b5‑1 plan adopted Dec 24, 2025. Vesting schedule for the option (1/4 after 1 year from Apr 1, 2025; monthly thereafter over 4 years) is noted.

Context
This was an option exercise followed by same‑day open‑market sales (effectively a cashless exercise), not an open‑market purchase. Exercises coupled with immediate sales are common for executives realizing proceeds from vested awards and are different from open‑market purchases, which some investors view as a stronger bullish signal. The transactions were governed by a 10b5‑1 plan, which means the sales were pre‑scheduled.